Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

D. Solomon, Scott; J.V. McMurray, John; A. Pfeffer, Marc; Wittes, Janet; Fowler, Robert; Finn, Peter; F. Anderson, William; G. Zauber, Ann; T. Hawk, Ernest; M. Bertagnolli, Monica

doi:10.1056/nejmoa050405

Public

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

Published in New England Journal of Medicine • Feb 16, 2005

Authors:

Scott D. Solomon

John J.V. McMurray

Marc A. Pfeffer

Abstract

BACKGROUND: Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern. ME...

Subject

Medicine

Celecoxib

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!